Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,676.55
(
-0.59%
)
US TECH 100
24,040.40
(
-0.38%
)
Dow Jones
46,549.03
(
-0.95%
)
Brent Oil
105.63
(
4.94%
)
Bitcoin
71,199.90
(
-3.71%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: lumpy9200 post# 32715

Monday, 08/14/2006 10:14:39 PM

Monday, August 14, 2006 10:14:39 PM

Post# of 257253
Re: ARNA vs AMLN in obesity

zebra4o1 is the expert on ARNA’s obesity program in these parts; he’s made several excellent posts you can look up.

I’m waiting to see the definitive Symlin obesity data in non-diabetics. I don’t rule out Symlin as a legitimate candidate just because it’s injected, but the efficacy and safety will have to be above reproach to give it a chance to be successful in the general-purpose obesity market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now